# US 2013/0280809 A1 · Reprogramming of cells to a new fate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280809 A1
- Document ID: US20130280809A1
- Status: Published application
- Kind: A1
- Application number: 13/704,214
- Filed: 2011-06-14
- Published: 2013-10-24
- Earliest claimed: 2010-06-14
- Assignees: The Scripps Research Institute
- Inventors: Jem A. Efe; Janghwan Kim; Saiyong Zhu; Simon Hilcove; Sheng Ding
- Web page: https://patentgrep.com/patent/US20130280809A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/33: Fibroblasts
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- C12N 5/0602: {Vertebrate cells}
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0619: {Neurons}
- C12N 5/0623: {Stem cells}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 15/85: for animal cells
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/605: Nanog
- C12N 2501/606: c-Myc
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2506/08: from cells of the nervous system
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions for transdifferentiation of an animal cell from (i) a first pluripotent cell fate to a second nonpluripotent cell fate or (ii) from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

## Claims

### Claim 1

A method of converting an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate, the method comprising:
increasing the quantity of at least one reprogramming transcription factor in an animal cell having the first cell fate to generate a cell that differentiates in response to lineage-specific differentiating factors to a second cell fate different from the first cell fate; and
submitting the cell that differentiates in response to lineage-specific differentiating factors to conditions that induce differentiation of the cell to generate a cell having the second non-pluripotent cell fate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the increasing step comprises limiting the development or growth of pluripotent cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the development or growth of pluripotent cells is limited by limiting the expression of the reprogramming transcription factor.

### Claim 4 (depends on 2)

The method of claim 2, wherein the development or growth of pluripotent cells is limited by contacting the cell that differentiates in response to lineage-specific differentiating factors with an inhibitor that inhibits the growth of pluripotent cells.

### Claim 5 (depends on 4)

The method of claim 4, wherein the inhibitor that inhibits the growth of pluripotent cells is a JAK inhibitor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell that differentiates in response to lineage-specific differentiating factors does not significantly express Nanog.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method occurs in the absence of exogenous LIF.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cell that differentiates in response to lineage-specific differentiating factors is not capable of forming a teratoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method does not comprise isolation or selection of cells between the increasing and submitting steps.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cell that differentiates in response to lineage-specific differentiating factors is not an induced pluripotent stem cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein the animal cell having the first cell fate is a fibroblast or a neural precursor cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cell having the second non-pluripotent cell fate is a cardiomyocyte.

### Claim 13 (depends on 12)

The method of claim 12, wherein the submitting step comprises contacting the cell that differentiates in response to lineage-specific differentiating factors with BMP4, a calcium channel agonist, a Gαs activating agent, a cAMP analog, and/or a GSK-3 inhibitor.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cell having the second non-pluripotent cell fate has a neuronal cell fate.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cell having the second non-pluripotent cell fate has a pancreatic cell fate.

### Claim 16 (depends on 1)

The method of claim 1, wherein the reprogramming factors are selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide.

### Claim 17 (depends on 1)

The method of claim 1, wherein the reprogramming factors comprise an Oct polypeptide, a Klf polypeptide, and a Sox2 polypeptide.

### Claim 18 (depends on 1)

The method of claim 1, wherein the reprogramming factors comprise an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide.

### Claim 19 (depends on 1)

The method of claim 1, wherein the time from initiation of the increasing step to the generation of the cell having the second non-pluripotent cell fate is no more than 25 days.

### Claim 20 (depends on 1)

The method of claim 1, wherein the time from initiation of the increasing step to the generation of the cell having the second non-pluripotent cell fate is no more than 20 days.

### Claim 21 (depends on 1)

The method of claim 1, wherein the time from initiation of the increasing step to the generation of the cell having the second non-pluripotent cell fate is no more than 15 days.

### Claim 22 (depends on 1)

The method of claim 1, wherein the time from initiation of the increasing step to the generation of the cell having the second non-pluripotent cell fate is between 10-22 days.

### Claim 23 (depends on 1)

The method of claim 1, wherein the conditions that induce differentiation are chemically defined conditions.

### Claim 24 (depends on 1)

The method of claim 1, wherein the increasing step is performed in vivo.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method is conducted at least partly in vivo.

### Claim 26 (depends on 25)

The method of claim 25, wherein the submitting step occurs by inducing the increasing step in a cell in a cellular context in vivo such that endogenous signals cause the cell to have the second non-pluripotent cell fate.

### Claim 27 (depends on 1)

The method of claim 1, wherein the method is conducted in vitro.

### Claim 28

A method of differentiating an animal cell into a cardiomyocyte, the method comprising:
contacting the animal cell with a GSK-3 inhibitor and/or a BMP protein under conditions to generate a cardiomyocyte.

### Claim 29 (depends on 28)

The method of claim 28, wherein the animal cell is a non-human animal cell.

### Claim 30 (depends on 28)

The method of claim 28, wherein the animal cell is a human cell.

### Claim 31 (depends on 28)

The method of claim 28, wherein the cell is a pluripotent cell.

### Claim 32 (depends on 28)

The method of claim 28, wherein the method is conducted at least partly in vivo.

### Claim 33 (depends on 28)

The method of claim 28, wherein the method is conducted in vitro.

### Claim 34 (depends on 1)

The method of claim 1, wherein the conditions are chemically defined conditions.

### Claim 35

A method of transdifferentiating an animal cell into a cardiomyocyte, comprising:
introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; and
contacting the non-pluripotent animal cell with a GSK-3 inhibitor, a calcium channel agonist, a Gαs activating agent, a cAMP analog, and/or a BMP protein under conditions to generate the cardiomyocyte;
thereby differentiating the non-pluripotent animal cell into the cardiomyocyte.

### Claim 36 (depends on 35)

The method of claim 35, wherein the method further comprises contacting the non-pluripotent animal cell with a JAK inhibitor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the non-pluripotent animal cell is contacted with the JAK inhibitor prior to contacting the cell with the GSK-3 inhibitor, the calcium channel agonist, the Gαs activating agent, the cAMP analog, and/or the BMP protein.

### Claim 38 (depends on 36)

The method of claim 36, wherein contacting with the JAK inhibitor comprises culturing the non-pluripotent animal cell in the presence of the JAK inhibitor.

### Claim 39 (depends on 38)

The method of claim 38, wherein the non-pluripotent animal cell is cultured in the presence of the JAK inhibitor for a period of about one to about nine days.

### Claim 40

A method of transdifferentiating an animal cell into a neural progenitor cell, the method comprising:
introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; and
contacting the non-pluripotent animal cell with FGF2, FGF4, and EGF under conditions to generate the neural progenitor cell;
thereby differentiating the non-pluripotent animal cell into the neural progenitor cell.

### Claim 41 (depends on 40)

The method of claim 40, wherein the method further comprises contacting the non-pluripotent animal cell with a Wnt inhibitor, a JAK inhibitor, or both a Wnt inhibitor and a JAK inhibitor.

### Claim 42 (depends on 41)

The method of claim 41, wherein the non-pluripotent animal cell is contacted with the Wnt inhibitor, the JAK inhibitor, or both the Wnt inhibitor and the JAK inhibitor prior to contacting the cell with FGF1, FGF4, and EGF.

### Claim 43

A method of transdifferentiating an animal cell into a retinal pigmented epithelium cell, the method comprising:
introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide;
contacting the non-pluripotent animal cell with FGF2, FGF4, and EGF under conditions to generate a neural progenitor cell; and
contacting the neural progenitor cell with a TGFβ inhibitor and a GSK-3 inhibitor to generate the retinal pigmented epithelium cell;
thereby differentiating the non-pluripotent animal cell into the retinal pigmented epithelium cell.

### Claim 44

A method of transdifferentiating an animal cell into a tyrosine hydroxylase (TH)-positive neuronal cell, the method comprising:
introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; and
contacting the non-pluripotent animal cell with FGF8 and SHH under conditions to generate the TH-positive neuronal cell;
thereby differentiating the non-pluripotent animal cell into the TH-positive neuronal cell.

### Claim 45

A method of transdifferentiating an animal cell into a pancreatic lineage cell, the method comprising:
(1) introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; and
(2) under conditions to generate the pancreatic lineage cell,
(a) contacting the non-pluripotent animal cell with a TGFβ/Activin/Nodal family member and a JAK inhibitor;
(b) contacting the cell of step (2)(a) with a TGFβ/ALK5 receptor inhibitor, BMP4, bFGF, and RA; and
(c) contacting the cell of step (2)(b) with nicotinamide;
thereby differentiating the non-pluripotent animal cell into the pancreatic lineage cell.

### Claim 46

A method of transdifferentiating an animal cell into an induced definitive endoderm (iDE) cell, the method comprising:
introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; and
contacting the non-pluripotent animal cell with a GSK-3 inhibitor, an HDAC inhibitor, and a TGFβ/Activin/Nodal family member under conditions to generate the iDE cell;
thereby differentiating the non-pluripotent animal cell into the iDE cell.

### Claim 47

A method of transdifferentiating an animal cell into a pancreatic beta cell, the method comprising:
(1) introducing into a non-pluripotent animal cell having a first non-pluripotent cell fate one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide; or contacting a non-pluripotent animal cell having a first non-pluripotent cell fate with one or polypeptides selected from the group consisting of an Oct polypeptide, a Klf polypeptide, a Sox2 polypeptide and a Myc polypeptide;
(2) contacting the non-pluripotent animal cell with a GSK-3 inhibitor, an HDAC inhibitor, and a TGFβ/Activin/Nodal family member under conditions to generate an iDE cell; and
(3) under conditions to generate the pancreatic beta cell,
(a) contacting the iDE cell with FGF7, RA, a Hedgehog pathway inhibitor, a BMP inhibitor, and a TGFβ/ALK5 receptor inhibitor;
(b) contacting the cell of step (3)(a) with EGF and a Notch inhibitor; and
(c) contacting the cell of step (3)(b) with bFGF and nicotinamide;
thereby differentiating the non-pluripotent animal cell into the pancreatic beta cell.

### Claim 48 (depends on 47)

The method of claim 47, wherein step (3) further comprises contacting with extendin 4.
